Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

Delcath Systems, Inc. (DCTH) announced the publication of a clinical study in Therapeutic Advances in Medical Oncology. The study, conducted by researchers at the University of Tübingen, Germany, demonstrates that Delcath's CHEMOSAT Hepatic Delivery System significantly improves melanoma-specific survival (MSS) in patients with liver metastases from uveal melanoma when used as a first-line therapy. This retrospective study analyzed 167 patients diagnosed between 2005 and 2021 and found that those receiving ...